Early pre-exposure prophylaxis (PrEP) initiation and continuation among pregnant and postpartum women in antenatal care in Cape Town, South Africa

Dvora Leah Joseph Davey, Rufaro Mvududu, Nyiko Mashele, Maia Lesosky, Nehaa Khadka, Linda-Gail Bekker, Pamina Gorbach, Thomas J Coates, Landon Myer, Dvora Leah Joseph Davey, Rufaro Mvududu, Nyiko Mashele, Maia Lesosky, Nehaa Khadka, Linda-Gail Bekker, Pamina Gorbach, Thomas J Coates, Landon Myer

Abstract

Introduction: Pre-exposure prophylaxis (PrEP) is a safe and effective prevention strategy to reduce women's risk of HIV in pregnancy and postpartum. Effective PrEP protection requires daily PrEP adherence, but little is known about maternal PrEP continuation and factors that influence PrEP use.

Methods: The PrEP in pregnancy and postpartum (PrEP-PP) study enrolled consenting pregnant, HIV-negative women at first antenatal care (ANC) visit with follow-up through 12 months postpartum. Eligible and consenting women and girls ≥16 years received HIV prevention counselling and were offered PrEP. Interviewers collected socio-demographic and behavioural data from participants at each visit. We analysed the proportion of women who initiated PrEP and the proportion who continued PrEP after 3 months with associated correlates by estimating the prevalence ratio adjusting for a priori confounders.

Results: Between August 2019 and October 2021, we enrolled 1201 pregnant women (median gestation 21 weeks; age 26 years); 84% of women initiated PrEP at their first ANC visit (n = 1014); 55% were married or cohabiting. Overall, 66% of women on PrEP returned for a repeat prescription at 1 month; 58% returned at 3 months (n = 493 of 844). Almost one-half of women on PrEP reported a side effect at 1 month, mostly nausea/vomiting. Women on PrEP in the first and second trimesters had higher odds of reporting side effects (aOR 2.61; 95% CI 1.17-5.84) versus postpartum women. Women who reported side effects continued with PrEP less than those who did not report side effects (aPR = 0.87; 95% CI 0.77-0.97). Women with ≥1 previous pregnancy (aPR = 0.76; 95% CI 0.57-1.01) or were postpartum (aPR 0.85; 95% CI 0.75-0.97) were less likely to continue PrEP compared to women who were primigravid or pregnant. Women who reported having an HIV+ partner (aPR = 1.45; 95% CI 1.13-1.85) or high HIV risk perception (aPR = 1.20, 95% CI = 1.01-1.41) were more likely to continue on PrEP than those who had HIV-negative partners or low risk perception.

Conclusions: PrEP initiation and early continuation were high in this setting, compared to other studies in women. Being postpartum and experiencing side effects were associated with lower PrEP continuation, presenting opportunities for counselling on early transient side effects. Interventions for postpartum women on PrEP are needed.

Trial registration: ClinicalTrials.gov NCT03826199.

Keywords: South Africa; adherence; breastfeeding; cohort studies; pre-exposure prophylaxis; pregnant.

Conflict of interest statement

We received the study drug (Truvada®) from Gilead Sciences (Foster City, CA, USA) and STI test kits from Cepheid Inc. (Sunnyvale, CA, USA).

© 2022 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Figures

Figure 1
Figure 1
Side effects reported by pregnant women on PrEP and how much it bothered them.
Figure 2
Figure 2
Reasons for missing PrEP doses among pregnant and postpartum women at 3 month follow‐up (n=387 women who missed 1+ PrEP doses).

References

    1. Drake AL, Wagner A, Richardson B, John‐Stewart G. Incident HIV during pregnancy and postpartum and risk of mother‐to‐child HIV transmission: a systematic review and meta‐analysis. PLoS Med. 2014;11(2):e1001608.
    1. Thomson KA, Hughes J, Baeten JM, John‐Stewart G, Celum C, Cohen CR, et al. Increased risk of female HIV‐1 acquisition throughout pregnancy and postpartum: a prospective per‐coital act analysis among women with HIV‐1 infected partners. J Infect Dis. 2018;218:16–25.
    1. Mofenson LM. Tenofovir pre‐exposure prophylaxis for pregnant and breastfeeding women at risk of HIV infection: the time is now. PLoS Med. 2016;13(9):e1002133.
    1. Pintye J, Davey DLJ, Wagner AD, John‐Stewart G, Baggaley R, Bekker LG, et al. Defining gaps in pre‐exposure prophylaxis delivery for pregnant and post‐partum women in high‐burden settings using an implementation science framework. Lancet HIV. 2020;7(8):e582–92.
    1. Johnson LF, Stinson K, Newell ML, Bland RM, Moultrie H, Davies MA, et al. The contribution of maternal HIV seroconversion during late pregnancy and breastfeeding to mother‐to‐child transmission of HIV. J Acquir Immune Defic Syndr. 2012;59(4):417–25.
    1. le Roux SM, Abrams EJ, Nguyen KK, Myer L. HIV incidence during breastfeeding and mother‐to‐child transmission in Cape Town, South Africa. AIDS. 2019;33(8):1399–401.
    1. Joseph Davey DL, Bekker LG, Gomba Y, Coates T, Myer L, Johnson LF. Modelling the potential impact of providing preexposure prophylaxis in pregnant and breastfeeding women in South Africa. AIDS. 2019;33(8):1391–5.
    1. Joseph Davey DL, Pintye J, Baeten JM, Aldrovandi G, Baggaley R, Bekker LG, et al. Emerging evidence from a systematic review of safety of pre‐exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading? J Int AIDS Soc. 2020;23(1):e25426.
    1. Wang L, Kourtis AP, Ellington S, Legardy‐Williams J, Bulterys M. Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. Clin Infect Dis. 2013;57(12):1773–81.
    1. Ministry of Health NASCP . Guidelines on use of antiretroviral drugs for treating and preventing HIV infection in Kenya 2016. Nairobi; 2016.
    1. World Health Organization . WHO Technical brief: preventing HIV during pregnancy and breastfeeding in the context of pre‐exposure prophylaxis (PrEP). Geneva: World Health Organization; 2017.
    1. AVAC . Global PrEP Tracker. 2021.
    1. AVAC . A snapshot of PrEP scale up, registration and resources for South Africa. South Africa: PrEP Watch; 2020.
    1. Kinuthia J, Pintye J, Abuna F, Mugwanya KK, Lagat H, Onyango D, et al. Pre‐exposure prophylaxis uptake and early continuation among pregnant and post‐partum women within maternal and child health clinics in Kenya: results from an implementation programme. Lancet HIV. 2020;7(1):e38–48.
    1. Joseph Davey DL, Knight L, Markt‐Maloney J, Tsawe N, Gomba Y, Mashele N, et al. “I had Made the Decision, and No One was Going to Stop Me” —Facilitators of PrEP Adherence During Pregnancy and Postpartum in Cape Town, South Africa. AIDS and Behavior. 2021;25(12):3978–3986. 10.1007/s10461-021-03320-x
    1. Eakle R, Weatherburn P, Bourne A. Understanding user perspectives of and preferences for oral PrEP for HIV prevention in the context of intervention scale‐up: a synthesis of evidence from sub‐Saharan Africa. J Int AIDS Soc. 2019;22(Suppl 4):e25306.
    1. Velloza J, Khoza N, Scorgie F, Chitukuta M, Mutero P, Mutiti K, et al. The influence of HIV‐related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. J Int AIDS Soc. 2020;23(3):e25463.
    1. Scorgie F, Khoza N, Baron D, Lees S, Harvey S, Ramskin L, et al. Disclosure of PrEP use by young women in South Africa and Tanzania: qualitative findings from a demonstration project. Cult Health Sex. 2021;23:252–72.
    1. Janes H, Corey L, Ramjee G, Carpp LN, Lombard C, Cohen MS, et al. Weighing the evidence of efficacy of oral PrEP for HIV prevention in women in Southern Africa. AIDS Res Hum Retroviruses. 2018;34(8):645–56.
    1. Joseph Davey DL, Bekker LG, Gorbach PM, Coates TJ, Myer L. Delivering preexposure prophylaxis to pregnant and breastfeeding women in sub‐Saharan Africa: the implementation science frontier. AIDS. 2017;31(16):2193–7.
    1. Davey DLJ, Bekker LG, Mashele N, Gorbach P, Coates TJ, Myer L. PrEP retention and prescriptions for pregnant women during COVID‐19 lockdown in South Africa. Lancet HIV. 2020;7(11):e735.
    1. Pillay D, Stankevitz K, Lanham M, Ridgeway K, Murire M, Briedenhann E, et al. Factors influencing uptake, continuation, and discontinuation of oral PrEP among clients at sex worker and MSM facilities in South Africa. PLoS One. 2020;15(4):e0228620.
    1. Celum CL, Delany‐Moretlwe S, Baeten JM, van der Straten A, Hosek S, Bukusi EA, et al. HIV pre‐exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. J Int AIDS Soc. 2019;22(Suppl 4):e25298.
    1. Eakle R, Gomez GB, Naicker N, Bothma R, Mbogua J, Cabrera Escobar MA, et al. HIV pre‐exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: results from a prospective observational demonstration project. PLoS Med. 2017;14(11):e1002444.
    1. Mugwanya KK, Pintye J, Kinuthia J, Abuna F, Lagat H, Begnel ER, et al. Integrating preexposure prophylaxis delivery in routine family planning clinics: a feasibility programmatic evaluation in Kenya. PLoS Med. 2019;16(9):e1002885.
    1. Heffron R, Ngure K, Odoyo J, Bulya N, Tindimwebwa E, Hong T, et al. Pre‐exposure prophylaxis for HIV‐negative persons with partners living with HIV: uptake, use, and effectiveness in an open‐label demonstration project in East Africa. Gates Open Research. 2018;1:3. 10.12688/gatesopenres.12752.2
    1. Blackstock OJ, Patel VV, Felsen U, Park C, Jain S. Pre‐exposure prophylaxis prescribing and retention in care among heterosexual women at a community‐based comprehensive sexual health clinic. AIDS Care. 2017;29(7):866–9.
    1. Pintye J, Drake AL, Kinuthia J, Unger JA, Matemo D, Heffron RA, et al. A risk assessment tool for identifying pregnant and postpartum women who may benefit from preexposure prophylaxis. Clin Infect Dis. 2017;64(6):751–8.
    1. Kilembe W, Wall KM, Mokgoro M, Mwaanga A, Dissen E, Kamusoko M, et al. Implementation of couples' voluntary HIV counseling and testing services in Durban, South Africa. BMC Public Health. 2015;15:601.
    1. Pintye J, Drake AL, Begnel E, Kinuthia J, Abuna F, Lagat H, et al. Acceptability and outcomes of distributing HIV self‐tests for male partner testing in Kenyan maternal and child health and family planning clinics. AIDS. 2019;33(8):1369–78.
    1. Thomson KA, Baeten JM, Mugo NR, Bekker LG, Celum CL, Heffron R. Tenofovir‐based oral preexposure prophylaxis prevents HIV infection among women. Curr Opin HIV AIDS. 2016;11(1):18–26.
    1. Corneli A, Perry B, McKenna K, Agot K, Ahmed K, Taylor J, et al. Participants' explanations for nonadherence in the FEM‐PrEP clinical trial. J Acquir Immune Defic Syndr. 2016;71(4):452–61.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner